FDA Recalls MIOSTAT Carbachol Solution Nationwide for Temperature Abuse
McKesson Medical-Surgical is recalling MIOSTAT (Carbachol Intraocular Solution) nationwide due to temperature abuse during distribution that may affect medication stability.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II classification indicates potential for adverse health consequences, but this temperature-abuse manufacturing deviation lacks reported illnesses or injuries, meeting the threshold for moderate severity as a precautionary pharmaceutical recall.
Plain-English summary
MIOSTAT (Carbachol Intraocular Solution, USP) 0.01%, a prescription eye medication manufactured by Alcon Surgical Inc. and distributed by McKesson Medical-Surgical Inc., is being recalled nationwide due to cGMP deviations involving temperature abuse.
The temperature exposure occurred during product distribution and may have compromised the stability of the medication. The recall includes 8 boxes containing 12 vials each (1.5 mL vials), NDC 0065-0023-15, which were distributed across the United States.
McKesson Medical-Surgical Inc. has notified customers and provided information regarding which product lots may have been affected based on the dates the medication was shipped to individual facilities.
The recalled product
- Product
- MIOSTAT (CARBACHOL)
- Brand
- MIOSTAT
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug — Ophthalmic
- Hazard
- temperature-abuse
- manufacturing-deviation
- product-stability
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27